Increased costs of HIV care associated with aging in an HIV-infected population

HIV Medicine

Volumn 16, Issue 1, 2015, Pages 38-47

  Krentz, H B ^a,b   Gill, M J ^a,b  

^a Southern Alberta Clinic   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Aging; Canada; Cost of care; Health policy; HIV AIDS

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTPATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; AGING; CANADA; COMPARATIVE STUDY; ECONOMICS; EPIDEMIOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MIDDLE AGED; PATIENT ATTITUDE; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGING; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANADA; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; YOUNG ADULT;

EID: 84916233365     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12176     Document Type: Article

References (49)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-299.
2. HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24: 123-137.
3. Hasse B, Ledergerber B, Furrer H etal. Morbidity and aging in HIV-Infected persons; The Swiss HIV Cohort Study. CID 2011; 53: 1130-1139.
4. Centers for Disease Control and Prevention. HIV Surveillance Report 2011; 23. Available at http://www.cdc.gov/hiv/surveillance/resources/reports/2011report/index.htm (accessed 21 March 2013).
5. Prejean J, Song R, Hernandez A etal. Estimated HIV incidence in the United States, 2006-2009. PLos ONE 2011; 6: e17502.
6. HIV/AIDS epidemiological update. Public Health Agency of Canada. 2010. Available at http://www.phac-aspc.gc.ca/aids-sida/publication/epi/2010/index-eng.php (accessed 21 March 2013).
7. Althoff KN, Gebo KA, Grange SJ etal. CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther 2010; 7: 45. doi: 10.1186/1742-6405-7-45.
8. High KP, Brennan-Ing M, Clifford DB etal. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. JAIDS 2012; 60 (Suppl 1): S1-S18.
9. Brooks JT, Buchacz K, Gebo KA, Mermin J. HIV infection and older Americans: the public health perspective. Amer J Pub Health 2012; 102: 1515-1526.
10. Bhavan KP, Kamplath VN, Overton ET. The aging of the HIV epidemic. Curr HIV/AIDS Rep 2008; 5: 150-158.
11. Phillips AN, Lee CA, Elford J etal. More rapid progression to AIDS in older HIV-infected people: the role of CD4- T-cell counts. J Acquir Immune Defic Syndr 1991; 4: 970-975.
12. Cherner M, Ellis RJ, Lazzaretto D etal. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS 2004; 18 (Suppl 1): S27-S34.
13. Valcour V, Shikuma C, Shiramizu B etal. Higher frequency of dementia in older HIV-1 individuals: the Hawaii aging with HIV-1 Cohort. Neurology 2004; 63: 822-827.
14. Eggar M, May M, Chene G etal. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
15. Ewings FM, Bhaskaran K, McLean K etal. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS 2008; 22: 89-95.
16. Rodriquez-Penny AT, Iudicello JE, Riggs RK, Doyle K, Ellis RJ, Letendre SL. Co-morbidities in persons with HIV: increased burden with older age and negative effect on Health Related Quality of Life. AIDS Patient Care and STDs 2013; 27: 5-16.
17. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, aging, and non-AIDS related mortality. BMJ 2009; 338: a3172. doi: 10.1136/bmj.a3172.
18. Onen NF, Turner Overton E, Seyfried W etal. Aging and HIV infection: a comparison between older HIV-Infected persons and the general population. HIV Clin Trials 2010; 11: 100-109.
19. Guaraldi G, Orlando G, Zona S etal. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53: 1120-1126.
20. Gebo K. HIV and aging. Implication for patient management. Drugs Aging 2006; 23: 897-913.
21. Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 2010; 7: 69-76. doi:10.1007/s11904-010-0041-9.
22. Effros RB, Fletcher CV, Gebo K etal. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008; 47: 542-553.
23. Gebo KA, Fleishman JA, Conviser R etal. Contemporary costs of HIV Health Care in the HAART Era. AIDS 2010; 24: 2705-2715.
24. Krentz HB, Gill MJ. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006. HIV Med 2008; 9: 721-730.
25. Fleishman JA, Yehia BR, Moore RD, Gebo KA, Research HIV. Network the economic burden of late entry into medical care for patients with HIV infection. Med Care 2010; 48: 1071-1079.
26. 3) of HIV infection over a 15-year period. AIDS Res Treat 2012; 2012: Article ID 757135. doi:10.1155/2012/757135.
27. Krentz HB, Gill MJ. Despite CD4 cell count rebound the higher initial costs of medical care for HIV-infected patients persist 5 years after presentation with CD4 cell counts less than 350. AIDS 2010; 24: 2750-2753.
28. Lehnert T, Heider D, Leicht H etal. Health care utilization and costs of elderly person with multiple chronic conditions. Med Care Res Rev 2011; 68: 387-420.
29. Guaraldi G, Zona S, Menozzi M etal. Cost of non-infectious comorbidities in patients with HIV. ClinicoEconomics Outcomes Res 2013; 5: 481-488.
30. Shoen JC, Erlandson KM, Anderson PL. Clinical pharmacokinetics of antiretroviral drugs in older persons. Exp Opin Drug Meth Toxicol 2013; 9: 573-588.
31. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007; 167: 684-691.
32. Rhee M, Greenblatt DJ. Pharmacologic consideration for the use of antiretroviral agents in the elderly. J Clin Pharmacol 2008; 48: 1212-1225.
33. Marzolini CM, Back D, Weber R etal. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66: 2107-2111.
34. Haas D, Kuritzkes D, Ritchie M etal. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the national institute of allergy and infectious diseases. HIV Clin Trials 2011; 12: 277-285.
35. Krentz HB, Ko K, Beckthold B, Gill MJ. The cost of antiretroviral drug resistance in HIV+ patients. Antivir Ther 2014. doi: 10.3851/IMP2709.
36. Nachega JB, Hsu AJ, Uthman OA, Spinewine A, Pham PA. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS 2012; 26: S39-S53.
37. Hinkin CH, Hardy JH, Mason KL etal. Medication adherence in HIV-infected adults: effects on patient's age, cognitive status, and substance abuse. AIDS 2004; 18 (Suppl 1): S19-S25.
38. Muller V, Ledergerber B, Perrin L etal. Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS 2006; 20: 889-894.
39. Althoff KN, Justice AC, Gange SJ etal. Virologic and immunologic responses to HAART by age and regimen class. AIDS 2010; 24: 2469-2479.
40. Cuzin L, Delpierre C, Gegard S, Massip P. Marchou B Immunologic and clinical responses to highly active antiretroviral therapy in patient with HIV infection aged >50 years. Clin Infect Dis 2007; 45: 654-657.
41. Antiretroviral Therapy Cohort Collaboration. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005; 165: 416-423.
42. Chen RY, Accortt NA, Westfall AO etal. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006; 42: 1003-1010.
43. Buchacz K, Baker RK, Moorman AC etal. HIV Outpatient Study (HOPS) Investigators. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS 2008; 22: 1345-1354.
44. Davalos DM, Hlaing WM, Kim S, de la Rosa M. Recent trends in hospital utilization and mortality for HIV infection: 2000-2005. J Natl Med Assoc 2010; 102: 1131-1138.
45. Berry SA, Fleishman JA, Moore RD, Gebo KA, for the HIV Research Network. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001-2008. Arch Intern Med 2005; 165: 416-423.
46. Crum-Cianflone NF, Gradnits G, Echols S etal. Trends and causes of hospitalizations among HIV-infected persons during the late HAART Era: what is the impact of CD4 counts and HAART use? JAIDS 2010; 54: 248-257.
47. Krentz HB, Dean S, Gill MJ. Longitudinal assessment (1995-2003) of hospitalizations of HIV-infected patients within a geographical population in Canada. HIV Med 2006; 7: 457-466.
48. Krentz HB, Cosman I, Lee K, Mah Ming J, Gill MJ. Pill burden in HIV infection: 20 years of experience. Antivir Ther 2012; 17: 833-840.
49. Krentz HB, Gill MJ. Impact of practice changes on an antiretroviral budget in a HIV care program. Dis Manag Health Outcomes 2005; 13: 209-217.